OTC Markets Group Welcomes Vaxart, Inc. to OTCQX
OTC Markets Group (OTCQX: OTCM) announced that Vaxart (OTCQX: VXRT), a clinical-stage biotechnology company, has qualified to trade on the OTCQX庐 Best Market. The company has transitioned from its previous NASDAQ listing and commenced trading on the OTCQX under the symbol "VXRT" on July 8, 2025.
The OTCQX Market provides companies with cost-effective access to U.S. capital markets while maintaining high financial standards and corporate governance requirements. Vaxart's CEO Steven Lo emphasized the company's continued commitment to developing oral pill vaccines for public health advancement.
OTC Markets Group (OTCQX: OTCM) ha annunciato che Vaxart (OTCQX: VXRT), un'azienda biotecnologica in fase clinica, ha ottenuto l'idoneit脿 per negoziare sul mercato OTCQX庐 Best Market. La societ脿 ha lasciato la sua precedente quotazione al NASDAQ ed ha iniziato a essere quotata su OTCQX con il simbolo "VXRT" l'8 luglio 2025.
Il mercato OTCQX offre alle aziende un accesso economico ai mercati finanziari statunitensi, mantenendo al contempo elevati standard finanziari e requisiti di governance aziendale. Il CEO di Vaxart, Steven Lo, ha sottolineato l'impegno continuo della societ脿 nello sviluppo di vaccini orali in forma di pillola per il progresso della salute pubblica.
OTC Markets Group (OTCQX: OTCM) anunci贸 que Vaxart (OTCQX: VXRT), una empresa biotecnol贸gica en etapa cl铆nica, ha calificado para cotizar en el mercado OTCQX庐 Best Market. La compa帽铆a ha dejado su listado previo en NASDAQ y comenz贸 a cotizar en OTCQX bajo el s铆mbolo "VXRT" el 8 de julio de 2025.
El mercado OTCQX brinda a las empresas un acceso rentable a los mercados de capitales de EE.UU., manteniendo altos est谩ndares financieros y de gobernanza corporativa. El CEO de Vaxart, Steven Lo, destac贸 el compromiso continuo de la empresa con el desarrollo de vacunas orales en forma de pastilla para el avance de la salud p煤blica.
OTC Markets Group (OTCQX: OTCM)電� 鞛勳儊 雼硠鞚� 靸濍獏瓿淀暀 須岇偓鞚� Vaxart (OTCQX: VXRT)臧� OTCQX庐 Best Market鞐愳劀 瓯半灅 鞛愱博鞚� 須嶋摑頄堧嫟瓿� 氚滍憸頄堨姷雼堧嫟. 鞚� 須岇偓電� 鞚挫爠 NASDAQ 靸侅灔鞚� 膦呺頃橁碃 2025雲� 7鞗� 8鞚茧秬韯� "VXRT" 鞁臣搿� OTCQX鞐愳劀 瓯半灅毳� 鞁滌瀾頄堨姷雼堧嫟.
OTCQX 鞁滌灔鞚� 旮办梾霌れ澊 氙戈淡 鞛愲掣 鞁滌灔鞐� 牍勳毄 須湪鞝侅溂搿� 鞝戧芳頃� 靾� 鞛堧弰搿� 頃橂┐靹滊弰 雴掛潃 鞛 旮办瓿� 旮办梾 歆�氚瓣惮臁� 鞖旉贝鞚� 鞙犾頃╇媹雼�. Vaxart鞚� CEO鞚� Steven Lo電� 瓿奠 氤搓贝 氚滌爠鞚� 鞙勴暅 瓴疥惮鞖� 鞎岇暯 氚膘嫚 臧滊皽鞐� 雽�頃� 須岇偓鞚� 歆�靻嶌爜鞚� 鞚橃毳� 臧曥“頄堨姷雼堧嫟.
OTC Markets Group (OTCQX : OTCM) a annonc茅 que Vaxart (OTCQX : VXRT), une entreprise biotechnologique en phase clinique, a 茅t茅 qualifi茅e pour 锚tre cot茅e sur le march茅 OTCQX庐 Best Market. La soci茅t茅 a quitt茅 sa pr茅c茅dente cotation au NASDAQ et a commenc茅 脿 锚tre n茅goci茅e sur l鈥橭TCQX sous le symbole 芦 VXRT 禄 le 8 juillet 2025.
Le march茅 OTCQX offre aux entreprises un acc猫s rentable aux march茅s de capitaux am茅ricains tout en maintenant des normes financi猫res 茅lev茅es et des exigences de gouvernance d鈥檈ntreprise. Le PDG de Vaxart, Steven Lo, a soulign茅 l鈥檈ngagement continu de la soci茅t茅 dans le d茅veloppement de vaccins oraux sous forme de pilules pour le progr猫s de la sant茅 publique.
OTC Markets Group (OTCQX: OTCM) gab bekannt, dass Vaxart (OTCQX: VXRT), ein biotechnologisches Unternehmen in der klinischen Phase, sich f眉r den Handel am OTCQX庐 Best Market qualifiziert hat. Das Unternehmen hat seine vorherige NASDAQ-Notierung verlassen und begann am 8. Juli 2025 unter dem Symbol "VXRT" am OTCQX zu handeln.
Der OTCQX-Markt bietet Unternehmen kosteng眉nstigen Zugang zu den US-Kapitalm盲rkten und erf眉llt dabei hohe finanzielle Standards sowie Anforderungen an die Unternehmensf眉hrung. Vaxarts CEO Steven Lo betonte das anhaltende Engagement des Unternehmens f眉r die Entwicklung von oralen Pillenimpfstoffen zur F枚rderung der 枚ffentlichen Gesundheit.
- Qualification for OTCQX trading indicates meeting high financial standards and corporate governance requirements
- Cost-effective access to U.S. capital markets through OTCQX platform
- Delisting from NASDAQ to OTCQX represents a downgrade in trading venue
- Potential reduction in trading liquidity and institutional investor access
- May face challenges in maintaining analyst coverage and market visibility
NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced (OTCQX: VXRT), a clinical-stage biotechnology company, has qualified to trade on the OTCQX庐 Best Market. Vaxart, Inc. previously traded on NASDAQ.
Vaxart, Inc. begins trading today on OTCQX under the symbol 鈥淰XRT.鈥� U.S. investors can find current financial disclosure and AG真人官方-Time Level 2 quotes for the company on .
Trading on the OTCQX Market offers companies efficient, cost-effective access to the U.S. capital markets. Streamlined market requirements for OTCQX are designed to help companies lower the cost and complexity of being publicly traded, while providing transparent trading for their investors. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws.
鈥淲e thank OTC Markets Group for welcoming us and appreciate our investors for their continued support鈥� said Steven Lo, Vaxart CEO. 鈥淲e remain focused on making meaningful scientific progress in developing oral pill vaccines to potentially transform public health.鈥�
About Vaxart, Inc.
Vaxart聽is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform.聽Vaxart聽vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart聽believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart鈥檚 development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart鈥檚 first immune-oncology indication.聽Vaxart聽has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists
About OTC Markets Group Inc.
(OTCQX: OTCM) operates regulated markets for trading 12,000 U.S. and international securities. Our data-driven disclosure standards form the foundation of our public markets: OTCQX庐 Best Market, OTCQB庐 Venture Market, OTCID鈩笍 Basic Market and Pink Limited Market.
Our OTC Link庐 Alternative Trading Systems (ATSs) provide critical market infrastructure that broker-dealers rely on to facilitate trading. Our innovative model offers companies more efficient access to the U.S. financial markets.
OTC Link ATS, OTC Link ECN, OTC Link NQB, and MOON ATS are each SEC regulated ATS, operated by OTC Link LLC, a FINRA and SEC registered broker-dealer, member SIPC. To learn more about how we create better informed and more efficient markets, visit
.
Media Contact:
OTC Markets Group Inc., +1 (212) 896-4428,
FAQ
Why did Vaxart (VXRT) move from NASDAQ to OTCQX in July 2025?
What are the implications of Vaxart (VXRT) trading on OTCQX instead of NASDAQ?
What is Vaxart's (VXRT) current business focus after moving to OTCQX?
How can investors access Vaxart (VXRT) stock information on OTCQX?
What requirements did Vaxart (VXRT) meet to qualify for OTCQX trading?
